Already a Member?

Login

Not a Member?

Register
 
Home - Welcome

Exiqon Diagnostics Launches the First Molecular Diagnostics Industry Content Portal on MedTrust Online

Exiqon Diagnostics, a wholly owned subsidiary of Exiqon A/S, is a leader in personalizing medicine for cancer patients. As a CLIA and CAP-certified laboratory, Exiqon Diagnostics develops and performs novel molecular and cell-based oncology assays to help physicians individualize and optimize treatment selection for their patients. In addition to the Extreme Drug Resistance (EDR®) Assay, Exiqon Diagnostics offers an extensive test menu of prognostic and predictive molecular oncology biomarkers such as KRAS and BRAF mutation analyses for a more comprehensive evaluation of treatment options

Learn More

KRAS and BRAF Symposium Hosted by Dr. Alex Adjei Now Live!

Click here to participate in the discussion

Alex Adjei

Home - Welcome

OncoAssist Advisory Board

MedTrust Online has recruited a board of advisors of international stature. Each member is recognized as the leading expert in their respective field.   As a member, you get unprecedented access to their expertise, knowledge and experience.  Learn more about our Advisory Board here.

Learn More

MTOL in the News

  • MedTrust Online Surpasses 5,000 Users and Adds Dr. Henry Friedman To Oncology Advisory Board,

    Scottsdale, AZ- September 17, 2009- MedTrust Online, a world-leading provider of clinically-useful knowledge for oncologists seeking therapy options for challenging patient cancer cases, has surpassed 5,000 registered users on its free portal, Oncocentric.com. MedTrust Online also announced today that world-renowned oncologist Dr. Henry Friedman has joined MedTrust Online’s growing board of oncology advisors.

View all news